

2017 Pharmacogenetics in Psychiatry Meeting Schedule

7:45 AM- 8:45AM: Breakfast

8:45AM-9:00AM: *Introduction*
Anil Malhotra, Hofstra Northwell School of Medicine

SESSION I: PHARMACOGENETICS OF ANTIPSYCHOTIC DRUG RESPONSE I

9:00AM-9:20AM: *Association of rs1801133 MTHFR, rs1625579 MIR137, rs1800497 DRD2 Loci With Treatment Outcome of Schizophrenia Patients*
Hanna Kandratsenka, Centre for Addiction and Mental Health

9:20AM-9:40AM: *Identification of Clinical Features That Predict Future Weight Trajectory in a Novel Cohort of Clozapine Treated Patients*
Rebecca NS Harrison, King's College London

9:40AM-10:00AM: *Genetic Predictors of Antipsychotic Response to Lurasidone Identified in a Genome-Wide Association Study and by Schizophrenia Risk Genes*
Jiang Li, Northwestern University

10:00AM-10:20AM: *The Post-Synaptic Effector Gene ANKS1B: A Promising Lead from GWAS of Antipsychotic Drug Response*
Joseph L. McClay, Virginia Commonwealth University

10:20AM-10:40AM Break

SESSION II: PHARMACOGENETICS OF ANTIDEPRESSANT DRUG RESPONSE

10:40AM-11:00AM: *Pharmacogenetic-Guided Decision Support Tools for the Management of Major Depressive Disorder: A Systematic Review and Meta-Analysis of Prospective Randomized Controlled Trials*
Harris Eyre, Texas Medical Center

11:00AM-11:20AM: *Using the Genome-Wide Approach to Understand Genomic Contributions to Venlafaxine Response in Older Adults With Late-Life Depression*
Victoria Marshe, Centre for Addiction and Mental Health

11:20AM-11:40AM: *Whole Exome Sequencing Reveals Risk Factors in Treatment Resistant Depression*
Alessandro Serretti, University of Bologna

11:40AM-12:00PM: *The Form and Function of Pharmacogenetic-Based Decision Support Tools in Psychiatry*
Chad Bousman, University of Melbourne

12:00PM-1:30PM: Lunch

1:30PM-2:00PM: Plenary Lecture: *Big Data and Little Genes: Where Is It Leading?*
David Goldman, National Institute of Health

2017 Pharmacogenetics in Psychiatry Meeting Schedule

SESSION III: PHARMACOGENETICS OF ANTIPSYCHOTIC DRUG RESPONSE II

- 2:00PM-2:20PM: *Variation in Voltage-Gated Calcium Channel Genes Is Associated With Antipsychotic Treatment Response in a South African First Episode Schizophrenia Cohort*
Kevin O'Connell, Stellenbosch University
- 2:20PM-2:40PM: *RNA Signature of Treatment Response in First-Episode Psychosis*
Réjane Troudet, Institut National de la Santé et de la Recherche Médicale
- 2:40PM-3:00PM: *A Novel Procedure Allows for Creating Induced Neurons Directly From Human Patient Fibroblasts and Reveals Molecular Network Effects in 22Q11-Deletion-Syndrome*
Alexander Urban, Stanford University
- 3:00PM-3:20PM: *Schizophrenia Polygenic Risk Score Predicts Antipsychotic Treatment Response in Patients With First Episode Psychosis*
Jianping Zhang, Hofstra Northwell School of Medicine
- 3:20PM-3:30PM Break

SESSION IV: PHARMACOGENETICS OF ADHD AND SUBSTANCE ABUSE DISORDERS

- 3:30PM-3:50PM: *Epigenome-Wide Association Analysis and Replication Implicates Deregulation of PCSK9 in Alcohol Use Disorder*
Falk Lohoff, National Institute of Health
- 3:50PM-4:10PM: *Synergistic Effect of COMT and KIAA0319 Genes in Modulating ADHD Behaviors Using a Dynamic Pharmacogenetic-Behavioral Approach*
Weam Fageera, McGill University
- 4:10PM-4:30PM: *Pharmacogenetic Predictors of Methylphenidate Efficacy Response in Childhood ADHD*
Nicole M. Myer, Genomind, Inc.
- 4:30PM-4:50PM: *Druggable Genome in Attention Deficit Hyperactivity Disorder and Its Comorbid Conditions: New Avenues for Treatment*
Tetyana Zayats, University of Bergen
- 4:50-5:00PM Break
- 5:00PM-7:00PM Poster Session and Reception